Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) and Venus Concept (NASDAQ:VERO – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, earnings and dividends.
Risk & Volatility
Vivos Therapeutics has a beta of 6.04, meaning that its share price is 504% more volatile than the S&P 500. Comparatively, Venus Concept has a beta of -0.06, meaning that its share price is 106% less volatile than the S&P 500.
Earnings & Valuation
This table compares Vivos Therapeutics and Venus Concept”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vivos Therapeutics | $17.44 million | 0.11 | -$21.17 million | ($1.90) | -0.08 |
| Venus Concept | $58.88 million | 0.01 | -$47.00 million | ($48.84) | -0.01 |
Vivos Therapeutics has higher earnings, but lower revenue than Venus Concept. Vivos Therapeutics is trading at a lower price-to-earnings ratio than Venus Concept, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
26.4% of Vivos Therapeutics shares are held by institutional investors. Comparatively, 87.4% of Venus Concept shares are held by institutional investors. 2.1% of Vivos Therapeutics shares are held by company insiders. Comparatively, 28.0% of Venus Concept shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Vivos Therapeutics and Venus Concept’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vivos Therapeutics | -122.00% | -2,325.64% | -102.01% |
| Venus Concept | -92.76% | -1,904.25% | -85.22% |
Analyst Recommendations
This is a breakdown of recent recommendations for Vivos Therapeutics and Venus Concept, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vivos Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
| Venus Concept | 1 | 0 | 0 | 0 | 1.00 |
Vivos Therapeutics presently has a consensus target price of $2.80, suggesting a potential upside of 1,858.04%. Given Vivos Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Vivos Therapeutics is more favorable than Venus Concept.
About Vivos Therapeutics
Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado.
About Venus Concept
Venus Concept Inc., a medical technology company, develops, commercializes, and delivers minimally invasive and non-invasive medical aesthetic and hair restoration technologies, and related services in the United States and internationally. Its product portfolio includes Venus Legacy, a noninvasive device used in dermatological and general surgical procedures for females; Venus Versa, a multi-application device used in aesthetic and cosmetic procedures; Venus Versa Pro; and Venus Viva and Venus Viva MD, an advanced, portable, and fractional RF system for dermatological procedures requiring ablation and resurfacing of the skin. The company also offers Venus Fiore, a device that delivers non-thermal RF with massage and magnetic field pulses to treat various medical conditions; Venus Bliss and Venus Bliss Max for non-invasive lipolysis of the abdomen, back, thights, and flanks in individuals with a body mass index of 30 or less; Venus Glow, a dermabrasion device used to improve skin appearance; and NeoGraft, an advanced hair restoration technology with an automated FUE and implantation system. In addition, it provides Venus Velocity and Venus Epileve for hair removal, permanent hair reduction, and treatment of pseudofolliculitis barbae; ARTAS iX, a robotic system to assist physicians in identifying and extracting hair follicles units from the scalp during hair transplantation, creating recipient sites, and implanting the harvested hair follicles; and AI.ME an interactive, image-guided, and computer assisted system for fractional skin resurfacing. The company is headquartered in Toronto, Canada.
Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
